VieCure and Avera Health Confirm Clinical Validation and System-Wide Implementation of A.I. Platform
June 2, 2017
VieCure (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the VCurePrecision™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration between the two organizations.
VCurePrecision™ is an AI platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. It combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with codified expert knowledge to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance.
The strategic collaboration was formed in 2016 and has combined Avera’s clinical rules in genomic-based precision medicine and VieCure’s state-of-the-art AI platform for oncology. Avera is one of a handful of world leaders generating evidence-based knowledge through their practical application of genomic-based precision medicine for cancer patients.
Avera will be the first health system in the world to action patient data through the VCurePrecision™ platform. Implementation and training will occur late in 2017. The platform was validated in clinic and through the Avera Molecular Tumor Board in February through April of this year. Other leading NCI Cancer Centers in the USA are now contracting with VieCure and preparing for implementation in their oncology networks.
Gerry Hogue, President and CEO of VieCure, highlighted key differentiators of the platform. “VCurePrecision™ quite literally puts a virtual peer-to-peer consult in the hands of busy oncologists. Oncologists are able to accelerate decision-making, improve clinical throughput and efficiency, make better and more appropriate decisions at the individual patient level.”
Avera is an active member of the recognized Worldwide Innovative Networking (WIN) Consortium in personalized medicine, which is committed to rapidly translating genomic tailored discoveries into standards of care worldwide. They have established a next-generation tumor sequencing laboratory as part of the Avera Cancer Institute.
Dr. David Kapaska, Regional President and CEO of Avera McKennan Hospital & University Health Center, commented on the drivers of the relationship with VieCure. “Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values. As such we feel it is our obligation to share our knowledge and success in the cancer space with physicians, care teams and patients battling this disease. This fundamental belief is what drives our commitment to our collaboration with VieCure. It is our desire to help as many cancer patients and their families as much as possible and we feel our relationship with VieCure will help us accomplish this.”
We codify the world’s premier cancer guidance from clinical research centers around the world into a technology platform that considers each patient’s unique needs and supports the care team, patient and their family through diagnosis, treatment and follow-up. VieCure is headquartered in Greenwood Village, Colorado.